Thalidomide in cancer
Authors:
- S SinghalSSS Singhal
- J MehtaJMJ Mehta
- 1 February 2002
- journal article
- review article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 56 (1) , 4-12
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Thalidomide in the Treatment of Relapsed Multiple MyelomaMayo Clinic Proceedings, 2000
- Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drugBritish Journal of Haematology, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- IgG Antibody Subclasses, Tumor Necrosis Factor and IFN-γ Levels in Patients with Type II Lepra Reaction on Thalidomide TreatmentInternational Archives of Allergy and Immunology, 1998
- Regression of AIDS-Related Kaposi's Sarcoma During Therapy with ThalidomideClinical Infectious Diseases, 1996
- The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell culturesClinical and Experimental Immunology, 1995
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature reviewArchives of Dermatology, 1993
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.Journal of Experimental Medicine, 1993